Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each ...

Growth Capital Partners has made a minority investment into Strata, a specialist financial services consultancy delivering implementation and transformation services for asset managers, asset owners ...

CUPERTINO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kloudfuse, the AI-Powered Unified Observability platform, today announced the launch of Kloudfuse 3.5, transforming how enterprises monitor both ...

The Good Clinical Practice Micro-credential is designed to develop an interprofessional, interdisciplinary clinical and translational workforce with skills to meet the healthcare needs of the Buffalo ...

Clinical practice attrition has increased across the board from 2013 to 2019. Psychiatry, ob/gyn, and primary care have higher risk of attrition, as do doctors who care for older, sicker patients.

Community driven content discussing all aspects of software development from DevOps to design patterns. The Google Certified Professional Developer Practice Test validates your ability to design, ...

Domestic violence is one of the most common yet least reported crimes in the United States. Each year, nearly 10 million people are affected. Studies show that one in four women and one in nine men ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

AWS Outposts, Microsoft Azure Arc, and Google Cloud Anthos each offers its own approach to managing hybrid and multicloud environments. Here’s how they compare on cost, security, and management. The ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

Yesterday's lifting of the clinical hold on Rocket Pharmaceuticals, Inc.'s in vivo gene therapy RP-A501 is a major positive, but new protocols and lower dosing raise efficacy and safety concerns.